ME Therapeutics Holdings Inc.
METXF
$2.95
$0.000.09%
OTC PK
| 02/28/2026 | 11/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -40.26% | 0.13% | |||
| Depreciation & Amortization | 8.95% | -2.06% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.18% | -6.46% | |||
| Operating Income | 11.18% | 6.46% | |||
| Income Before Tax | 16.46% | -2.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 16.46% | -2.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.46% | -2.92% | |||
| EBIT | 11.18% | 6.46% | |||
| EBITDA | 12.09% | 6.63% | |||
| EPS Basic | 16.47% | -2.41% | |||
| Normalized Basic EPS | 16.98% | -1.92% | |||
| EPS Diluted | 14.12% | -2.41% | |||
| Normalized Diluted EPS | 16.98% | -1.92% | |||
| Average Basic Shares Outstanding | 0.87% | 0.62% | |||
| Average Diluted Shares Outstanding | 0.87% | 0.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||